Annexon, Inc. (ANNX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-30

Key Insights

Annexon, Inc. announced its Q4 2025 and full-year 2025 financial results, providing visibility into the company's recent performance and upcoming milestones.
The filing does not indicate any material changes to Annexon's leadership or significant business agreements, suggesting a continuation of the company's current strategic initiatives.
Investors should monitor Annexon's progress on its portfolio of drug candidates and the achievement of anticipated milestones, which could impact the company's future growth and valuation.

Want the newest filings?

This analysis covers the filing from 2026-03-30. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-14

Annexon, Inc. has updated its corporate presentation to reflect certain business and strategic updates, which may be used in upcoming meetings with analysts and investors.
The company is presenting at the 44th Annual J.P. Morgan Healthcare Conference, indicating its continued engagement with the investor community.
The presentation will be available on the company's website, providing investors with easy access to the latest information.

Filed: 2026-01-12

Annexon is accelerating its next-generation targeted immunotherapy platform to treat neuroinflammatory diseases, with multiple registrational milestones planned for 2026.
The company's press release indicates a strategic priority to advance its lead programs, which could lead to potential new treatment options for patients suffering from neuroinflammatory conditions.
Investors should monitor Annexon's progress in achieving these key milestones over the next year, as they could significantly impact the company's long-term growth trajectory.

Other reports for Annexon, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.